Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a widespread chronic microvascular complication of diabetes mellitus (DM), affects almost 30–50% of patients, and represents a leading cause of death of DM. Serotonin or 5-hydroxytryptamine (5-HT) is a multifunctional bioamine that has crucial roles in many physiolog...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2017/7680576 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563286009184256 |
|---|---|
| author | Yu Yang Hui Huang Zheng Xu Jun-kai Duan |
| author_facet | Yu Yang Hui Huang Zheng Xu Jun-kai Duan |
| author_sort | Yu Yang |
| collection | DOAJ |
| description | Diabetic kidney disease (DKD) is a widespread chronic microvascular complication of diabetes mellitus (DM), affects almost 30–50% of patients, and represents a leading cause of death of DM. Serotonin or 5-hydroxytryptamine (5-HT) is a multifunctional bioamine that has crucial roles in many physiological pathways. Recently, emerging evidence from experimental and clinical studies has demonstrated that 5-HT is involved in the pathogenesis of diabetic vascular complications. The 5-HT receptor (5-HTR) antagonists exert renoprotective effects by suppressing oxidative stress, suggesting that 5-HTR can be used as a potential target for treating DKD. In this review, therefore, we summarize the published information available for the involvement of 5-HT and 5-HTR antagonists in the pathogenesis of various diabetic complications with a particular focus of DKD. We conclude that 5-HTR is a potential therapeutic target for treating DKD, as it has been successfully applied in animal models and has currently being investigated in randomized and controlled clinical trials. |
| format | Article |
| id | doaj-art-47b0f4595cf3422e8823505a896be3f9 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-47b0f4595cf3422e8823505a896be3f92025-02-03T01:20:29ZengWileyJournal of Diabetes Research2314-67452314-67532017-01-01201710.1155/2017/76805767680576Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney DiseaseYu Yang0Hui Huang1Zheng Xu2Jun-kai Duan3Department of Endocrinology, Metabolism, and Genetics, Jiangxi Provincial Children’s Hospital, Nanchang, Jiangxi, ChinaDepartment of Endocrinology, Metabolism, and Genetics, Jiangxi Provincial Children’s Hospital, Nanchang, Jiangxi, ChinaPediatric Research Institute, Department of Pediatrics, University of Louisville, Louisville, KY, USADepartment of Cardiovascular Disorders, Jiangxi Provincial Children’s Hospital, Nanchang, Jiangxi, ChinaDiabetic kidney disease (DKD) is a widespread chronic microvascular complication of diabetes mellitus (DM), affects almost 30–50% of patients, and represents a leading cause of death of DM. Serotonin or 5-hydroxytryptamine (5-HT) is a multifunctional bioamine that has crucial roles in many physiological pathways. Recently, emerging evidence from experimental and clinical studies has demonstrated that 5-HT is involved in the pathogenesis of diabetic vascular complications. The 5-HT receptor (5-HTR) antagonists exert renoprotective effects by suppressing oxidative stress, suggesting that 5-HTR can be used as a potential target for treating DKD. In this review, therefore, we summarize the published information available for the involvement of 5-HT and 5-HTR antagonists in the pathogenesis of various diabetic complications with a particular focus of DKD. We conclude that 5-HTR is a potential therapeutic target for treating DKD, as it has been successfully applied in animal models and has currently being investigated in randomized and controlled clinical trials.http://dx.doi.org/10.1155/2017/7680576 |
| spellingShingle | Yu Yang Hui Huang Zheng Xu Jun-kai Duan Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease Journal of Diabetes Research |
| title | Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease |
| title_full | Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease |
| title_fullStr | Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease |
| title_full_unstemmed | Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease |
| title_short | Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease |
| title_sort | serotonin and its receptor as a new antioxidant therapeutic target for diabetic kidney disease |
| url | http://dx.doi.org/10.1155/2017/7680576 |
| work_keys_str_mv | AT yuyang serotoninanditsreceptorasanewantioxidanttherapeutictargetfordiabetickidneydisease AT huihuang serotoninanditsreceptorasanewantioxidanttherapeutictargetfordiabetickidneydisease AT zhengxu serotoninanditsreceptorasanewantioxidanttherapeutictargetfordiabetickidneydisease AT junkaiduan serotoninanditsreceptorasanewantioxidanttherapeutictargetfordiabetickidneydisease |